Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03311412 · ClinicalTrials.gov registry record · Phase 1
Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas
A Phase 1 study of Lymphoma and Solid Tumor, sponsored by Symphogen A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 89
- Enrollment target
- 4
- Study locations
NCT03311412 is a Phase 1 study of Lymphoma and Solid Tumor that has completed, run by Symphogen A/S. The registered enrollment target is 89 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (82% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT03311412, a Phase 1 study of Lymphoma and Solid Tumor, has completed, sponsored by Symphogen A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 89 participants
- Enrollment target
- 4
- Study locations
Study Summary
The primary purpose of this study is to see if Sym021 is safe and tolerable as monotherapy, in combination with either Sym022 or Sym023, and in Combination with both Sym022 and Sym023 for patients with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therapy is available.
Conditions Studied
Interventions
- DRUG Sym023
- DRUG Sym021
- DRUG Sym022
Study Locations (4)
Texas
- The University of Texas MD Anderson Cancer Center - Houston
- NEXT Oncology - San Antonio
Michigan
- South Texas Accelerated Research Therapeutics (START) Midwest - Grand Rapids
Ontario
- Princess Margaret Cancer Centre - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2017-11-20 |
| Est. Completion | 2022-03-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03311412
The ClinicalTrials.gov registry entry for NCT03311412 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (82% lower). The listed sponsor is Symphogen A/S, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Sym023 is the first listed.
NCT03311412 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Texas, Michigan, Ontario.
Frequently Asked Questions
What is clinical trial NCT03311412 about?
NCT03311412 is a clinical study titled "Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas". The primary purpose of this study is to see if Sym021 is safe and tolerable as monotherapy, in combination with either Sym022 or Sym023, and in Combination with both Sym022 and Sym023 for patients with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refract...
What is the current status of trial NCT03311412?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 89 participants. The study started on 2017-11-20. Estimated completion is 2022-03-23.
What conditions does trial NCT03311412 study?
This clinical trial studies the following conditions: Lymphoma, Solid Tumor, Metastatic Cancer.
What interventions are being tested in trial NCT03311412?
The interventions under investigation include: Sym023 (DRUG), Sym021 (DRUG), Sym022 (DRUG).
Who is sponsoring clinical trial NCT03311412?
This trial is sponsored by Symphogen A/S, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03311412 being conducted?
This trial has 4 study locations across Michigan, Texas, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.